Royalty financing
Also called royalty-based financing.
Royalty financing gives a business cash in exchange for payments tied to future sales, often from a specific product. It usually avoids issuing shares. Unlike a licensing royalty, the payment compensates a funder for providing capital, not an owner for permission to use intellectual property.
Key takeaways
- Payments come from sales, not profit. You can owe royalties while losing money.
- A royalty can end at a repayment cap, run for a fixed term or continue for the life of specified rights.
- No shares need be issued, but a deal can combine royalties with equity, warrants or security over assets.
- The sales definition and termination terms matter as much as the royalty rate.
How royalty financing works
A funder provides capital upfront. Your business then pays an agreed percentage of sales or an amount per unit sold. The agreement identifies which sales count, when payments are due and when the obligation ends.
For operating businesses, royalty financing often overlaps with revenue-based financing. Providers use the labels inconsistently: a deal might cover total company revenue or only one product.
Royalty financing also funds products before they generate sales, particularly in pharmaceuticals. That is different from an operating-business funder that needs existing revenue to assess repayment.
How a 5% royalty uses your cash
A startup receives $200,000 and pays 5% of collected sales until total payments reach $300,000. There are no fees, minimum payments or equity rights. Monthly sales stay constant.
| Monthly collected sales | Monthly royalty: sales × 5% | Time to reach $300,000 |
|---|---|---|
| $100,000 | $5,000 | 60 months |
| $200,000 | $10,000 | 30 months |
The company needs $300,000 ÷ 5% = $6 million in cumulative sales to finish paying.
The founder keeps their shares, but the cash cost above the funding received is $300,000 − $200,000 = $100,000. At a 40% gross margin, the royalty absorbs 5% ÷ 40% = 12.5% of gross profit before operating expenses.
The 1.5x repayment multiple is not an annual interest rate. Faster sales return the funder's money sooner, even though total payments stay the same.
What the document says
Royalty Pharma's 2024 Form 10-K distinguishes purchases of existing royalties from synthetic royalties created in exchange for funding. This illustrates an important distinction: financing can create a new claim on future product sales rather than transfer an existing royalty.
For your own agreement, read these provisions together:
- Revenue definition: gross sales, collected cash or net sales after specified deductions?
- Endpoint: repayment cap, expiration date or continuing rights?
- Early termination: what must you pay to buy out the royalty or sell the company?
- Security and default: what assets or remedies does the funder have if you breach the agreement?
"Net sales" does not mean net profit. Its deductions need to be defined.
Terms worth questioning
Question an uncapped royalty on your main product. Strong growth can make it far more expensive than a capped obligation. Ask whether an end date or buyout price is available.
Minimum payments deserve equal attention: they can remove the cash-flow flexibility that made the deal attractive. Check whether fees count toward the repayment cap and whether the funder also receives equity.
Prepare monthly revenue records, gross margins and customer concentration information for the funder's review. Include a downside forecast that shows what remains after royalty payments.
Royalty financing versus equity
| Issue | Royalty financing | Equity financing |
|---|---|---|
| Ownership | No shares required unless the deal includes them | Investor receives shares |
| Cash payments | Tied to sales under the agreement | Share ownership alone does not require sales-linked payments |
| Investor's upside | Defined by the royalty's scope and duration | Depends on share value and distributions |
| Main founder trade-off | Less operating cash | Less ownership and potentially less control |
Questions founders ask
Why does Kevin O'Leary always want royalties?
He does not always ask for them. The attraction for an investor is cash payments as products sell, rather than waiting for an acquisition or IPO. A royalty offer can also include equity, so "royalty" does not necessarily mean "no dilution."
Are royalties better than equity?
They can cost less if growth is strong and payments stop at a manageable cap. Equity preserves operating cash because shareholders are not owed payments simply because sales occur. A low-margin business may need that flexibility more than undiluted ownership.
What is a typical royalty payment?
There is no universal rate. A per-unit royalty, a percentage of product sales and a capped share of total revenue price different obligations. Compare total payments, timing and the sales definition, not just the headline percentage.
Is buying royalties a good investment?
Not automatically. Buying an existing music or patent royalty differs from financing a startup. Returns depend on the rights' duration, future sales and the payer's ability to pay. A repayment cap limits the obligation; it does not guarantee repayment.
